ECSP066656A - COMBINACIÓN DE (a) N-{5-[4-(4-METIL-PIPERAZINO-METIL)-BENZOILAMIDO]2-METILFENIL}-4-(3-PIRIDIL)-2-PIRIMIDINA-AMINA Y (b) POR LO MENOS UN INHIBIDOR DE HIPUSINACIÓN Y EL USO DE LA MISMA - Google Patents
COMBINACIÓN DE (a) N-{5-[4-(4-METIL-PIPERAZINO-METIL)-BENZOILAMIDO]2-METILFENIL}-4-(3-PIRIDIL)-2-PIRIMIDINA-AMINA Y (b) POR LO MENOS UN INHIBIDOR DE HIPUSINACIÓN Y EL USO DE LA MISMAInfo
- Publication number
- ECSP066656A ECSP066656A EC2006006656A ECSP066656A ECSP066656A EC SP066656 A ECSP066656 A EC SP066656A EC 2006006656 A EC2006006656 A EC 2006006656A EC SP066656 A ECSP066656 A EC SP066656A EC SP066656 A ECSP066656 A EC SP066656A
- Authority
- EC
- Ecuador
- Prior art keywords
- methyl
- combination
- piperazino
- methylphenyl
- amine
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 3
- -1 4-METHYL-PIPERAZINO-METHYL Chemical class 0.000 title 1
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 208000032839 leukemia Diseases 0.000 abstract 2
- 230000002062 proliferating effect Effects 0.000 abstract 2
- 239000005517 L01XE01 - Imatinib Substances 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 abstract 1
- 229960002411 imatinib Drugs 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La invención se refiere a un método para tratar un animal de sangre caliente, especialmente un ser humano, que tiene una enfermedad proliferante, que comprende administrar al animal una combinación que comprende (a) N-{5-[4-(4-metil-piperazino-metil)-benzoilamido]-2-metilfenil}-4-(3-piridil)-2-pirimidin-amina y (b) por lo menos un inhibidor de hipusinación, a una combinación que comprende (a) y (b) como se define anteriormente y opcionalmente por lo menos un portador farmacéuticamente aceptable para uso simultáneo, por separado o secuencial, en particular para el retraso de la progresión o el tratamiento de una enfermedad proliferante y finalmente al uso de por lo menos un inhibidor de hipusinación para la preparación de un medicamento para el retraso de la progresión o el tratamiento de leucemia, particularmente leucemia resistente al Imatinib.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US53156303P | 2003-12-19 | 2003-12-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP066656A true ECSP066656A (es) | 2006-10-25 |
Family
ID=34700180
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EC2006006656A ECSP066656A (es) | 2003-12-19 | 2006-06-19 | COMBINACIÓN DE (a) N-{5-[4-(4-METIL-PIPERAZINO-METIL)-BENZOILAMIDO]2-METILFENIL}-4-(3-PIRIDIL)-2-PIRIMIDINA-AMINA Y (b) POR LO MENOS UN INHIBIDOR DE HIPUSINACIÓN Y EL USO DE LA MISMA |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20080139480A1 (es) |
| EP (1) | EP1696917A1 (es) |
| JP (1) | JP2007514699A (es) |
| KR (1) | KR20060125810A (es) |
| CN (1) | CN1889952A (es) |
| AU (2) | AU2004298761A1 (es) |
| BR (1) | BRPI0417759A (es) |
| CA (1) | CA2547196A1 (es) |
| EC (1) | ECSP066656A (es) |
| IL (1) | IL176070A0 (es) |
| MA (1) | MA28240A1 (es) |
| MX (1) | MXPA06006925A (es) |
| NO (1) | NO20063326L (es) |
| RU (1) | RU2006125741A (es) |
| TN (1) | TNSN06182A1 (es) |
| WO (1) | WO2005058320A1 (es) |
| ZA (1) | ZA200603904B (es) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2402041T3 (es) | 2007-08-31 | 2013-04-26 | Janssen Pharmaceutica, N.V. | Combinaciones de imazalil e hidroxipiridonas |
| WO2009036753A2 (de) * | 2007-09-20 | 2009-03-26 | Schebo Biotech Ag | Neue pharmazeutika, verfahren zu ihrer herstellung und ihre verwendung in der medizinischen therapie |
| EP2252147B1 (en) | 2008-02-06 | 2012-12-05 | Janssen Pharmaceutica NV | Combinations of fludioxonil and pyrion compounds |
| EP2242365B1 (en) | 2008-02-06 | 2013-01-16 | Janssen Pharmaceutica NV | Combinations of pyrimethanil and pyrion compounds |
| WO2010048712A1 (en) * | 2008-10-31 | 2010-05-06 | University Health Network | Ciclopirox and cytarabine for the treatment of leukemic disorders |
| CN104945318A (zh) * | 2010-06-01 | 2015-09-30 | 拜欧赛里克斯公司 | 羟基吡啶酮衍生物、其药物组合物及其用于治疗增生性疾病的治疗用途 |
| CN103153309A (zh) * | 2010-06-01 | 2013-06-12 | 拜欧赛里克斯公司 | 使用6-环己基-1-羟基-4-甲基-2(1h)-吡啶酮治疗血液恶性肿瘤的方法 |
| EP2579718B1 (en) | 2010-06-10 | 2014-10-01 | Janssen Pharmaceutica, N.V. | Combinations of pyrimethanil and monoterpenes |
| EP2587920B1 (en) | 2010-07-01 | 2016-08-10 | Janssen Pharmaceutica, N.V. | Antimicrobial combinations of pyrion compounds with polyethyleneimines |
| CN103191110A (zh) * | 2013-03-28 | 2013-07-10 | 中国科学院昆明植物研究所 | 环吡酮及环吡酮胺在制备防治黑色素瘤的药物中的应用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0227593A1 (en) * | 1985-11-25 | 1987-07-01 | The Hospital For Sick Children | Use of chelating agents |
| GB8528983D0 (en) * | 1985-11-25 | 1986-01-02 | Ciba Geigy Ag | Use of chelating agents |
| MY129541A (en) * | 1996-06-25 | 2007-04-30 | Novartis Ag | Substituded 3,5-diphenyl-1,2,4-triazoles and their use as pharmaceutical metal chelators |
| JP4267326B2 (ja) * | 2001-03-23 | 2009-05-27 | エンゾン ファーマシューティカルズ，インコーポレーテッド | 置換芳香族酸を用いる抗癌剤プロドラッグ |
| AU2003251875A1 (en) * | 2002-07-15 | 2004-02-02 | Combinatorx, Incorporated | Combination therapy for the treatment of neoplasms |
-
2004
- 2004-12-17 US US10/583,107 patent/US20080139480A1/en not_active Abandoned
- 2004-12-17 WO PCT/EP2004/014439 patent/WO2005058320A1/en not_active Ceased
- 2004-12-17 BR BRPI0417759-2A patent/BRPI0417759A/pt not_active IP Right Cessation
- 2004-12-17 CN CNA2004800362740A patent/CN1889952A/zh active Pending
- 2004-12-17 CA CA002547196A patent/CA2547196A1/en not_active Abandoned
- 2004-12-17 KR KR1020067012061A patent/KR20060125810A/ko not_active Withdrawn
- 2004-12-17 AU AU2004298761A patent/AU2004298761A1/en not_active Abandoned
- 2004-12-17 RU RU2006125741/14A patent/RU2006125741A/ru not_active Application Discontinuation
- 2004-12-17 MX MXPA06006925A patent/MXPA06006925A/es not_active Application Discontinuation
- 2004-12-17 EP EP04804040A patent/EP1696917A1/en not_active Withdrawn
- 2004-12-17 JP JP2006544368A patent/JP2007514699A/ja active Pending
-
2006
- 2006-05-16 ZA ZA200603904A patent/ZA200603904B/en unknown
- 2006-05-31 IL IL176070A patent/IL176070A0/en unknown
- 2006-06-15 TN TNP2006000182A patent/TNSN06182A1/en unknown
- 2006-06-19 EC EC2006006656A patent/ECSP066656A/es unknown
- 2006-06-26 MA MA29141A patent/MA28240A1/fr unknown
- 2006-07-18 NO NO20063326A patent/NO20063326L/no not_active Application Discontinuation
-
2009
- 2009-04-28 AU AU2009201694A patent/AU2009201694A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| IL176070A0 (en) | 2006-10-05 |
| EP1696917A1 (en) | 2006-09-06 |
| RU2006125741A (ru) | 2008-01-27 |
| AU2004298761A1 (en) | 2005-06-30 |
| KR20060125810A (ko) | 2006-12-06 |
| MXPA06006925A (es) | 2006-08-23 |
| BRPI0417759A (pt) | 2007-04-10 |
| NO20063326L (no) | 2006-09-19 |
| MA28240A1 (fr) | 2006-10-02 |
| JP2007514699A (ja) | 2007-06-07 |
| WO2005058320A1 (en) | 2005-06-30 |
| ZA200603904B (en) | 2007-09-26 |
| CN1889952A (zh) | 2007-01-03 |
| US20080139480A1 (en) | 2008-06-12 |
| AU2009201694A1 (en) | 2009-05-28 |
| CA2547196A1 (en) | 2005-06-30 |
| TNSN06182A1 (en) | 2007-11-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP034823A (es) | Combinación que comprende n-{5-[4-(4-metil-piperazino-metil)-benzoilamido]-2-metilfenil}-4-(3-piridil)-2-pirimidin-amina, y un agente quimioterapéutico | |
| CY1114554T1 (el) | Ινδαζολια, βενζοτριαζολια και ν-αναλογα αυτων ως αναστολεις p38 κινασης | |
| ES2195345T3 (es) | Nueva forma de s-omeprazol. | |
| DE60137631D1 (de) | Ireovirus antikörpern zur behandlung von ras-vermittelten, proliferativen erkrankungen | |
| ES2572454T3 (es) | Tratamiento de enfermedades mediadas por los linfocitos T | |
| ECSP105253A (es) | Derivados de 5-feniltiazol y uso como inhibidores de pi3 cinasa | |
| EP1140840A4 (en) | -G (V) -CARBOXYARYL SUBSTITUTED DIPHENYL UREASINE AS RAF KINASE INHIBITORS | |
| ECSP066656A (es) | COMBINACIÓN DE (a) N-{5-[4-(4-METIL-PIPERAZINO-METIL)-BENZOILAMIDO]2-METILFENIL}-4-(3-PIRIDIL)-2-PIRIMIDINA-AMINA Y (b) POR LO MENOS UN INHIBIDOR DE HIPUSINACIÓN Y EL USO DE LA MISMA | |
| ATE521354T1 (de) | Kombination aus imatinib und einem histondeacetylase-hemmer zur behandlung von leukämie | |
| DE60019586D1 (de) | Myostatin genpromoter und inhibierung dessen aktivierung | |
| BR0212856A (pt) | Compostos de benzimidazol substuìdos e seu uso para o tratamento do câncer | |
| DE60310767D1 (de) | PYRAZOL-3,4-d-PYRIMIDINDERIVATE UND IHRE VERWENDUNG BEI DER BEHANDLUNG VON H.PYLORI-INFEKTIONEN | |
| AR053984A1 (es) | Combinacion de un inhibidor de proteina cinasa src y un inhibidor bcr - abl para el tratamiento de enfermedades proliferativas | |
| AU2003233946A1 (en) | 4-(4-methylpiperazin-1-ylmethyl)-n-(4-methyl-3(4-pyridin-3-yl)pyrimidin-2-yl-amino)phenyl)-benzamide for treating ang ii-mediated diseases | |
| BR0207649A (pt) | Combinação compreendendo um inibidor de transdução de sinal e um derivado de epotilona | |
| PL369402A1 (pl) | Nowe zastosowanie do leczenia choroby refluksowejprzełyku | |
| ATE397937T1 (de) | Medikament zur behandlung von pilzinfektionen; insbesondere aspergillose | |
| AU2003216621A8 (en) | Combination of glivec(sti571) with a cyclin-dependent kinase inhibitor, especially flavopiridol in the treatment of cancer | |
| ATE476183T1 (de) | Verfahren zur behandlung von soliden tumoren einschliesslich der verabreichung einer kombination mit imatinib und einem effluxpumpenhemmer | |
| DK1368478T3 (da) | Polypeptid, der fremkalder HIV-neutraliserende antistoffer | |
| CY1105354T1 (el) | Ένα παραγωγο θειαζολιδινοδιονης και η χρηση του σαν αντι-διαβητικο | |
| ATE414525T1 (de) | Homöpathisches mittel zur prophylaxe gegen von parasiten hervorgerufenen krankheiten | |
| EP1704863A3 (en) | Combination comprising N-5-4-(4-Methyl-Piperazino-Methyl-)Benzoyla Mido]-2-Methylphenyl -4-(3-Pyridyl)-2Phyrimidine-amine and a chemotherapeutic agent | |
| ITBO20000362A0 (it) | Metodo per il trattamento di articoli di tessuto e simili . | |
| ECSP992924A (es) | Nuevas dihidropirimidinas 2 heterociclicamente sustituidas (caso lea 32793) |